New cancer drug trial seeks to turn Patient's own immune cells against tumors
NCT ID NCT07293754
Summary
This early-stage trial is testing a new drug called RPTR-1-201, which is designed to guide a patient's own immune cells to attack advanced solid tumors. It will enroll about 150 adults to first find a safe dose and then see if the drug can shrink tumors, either alone or combined with another immunotherapy. The main goals are to check for side effects and see if the treatment shows signs of working against the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.